Hanns-Christian Mahler
CEO (Chief Enablement Officer) & Board Member, ten23 health
After studying pharmacy at the University of Mainz and pursuing a PhD in toxicology, Hanns-Christian wanted to contribute in a more practical way to developing medicines, particularly injectable biologics. After the loss of his father to cancer, it became his purpose to develop biotech injectable medicines.
He previously worked at Project Leader and Formulation and Sterile Manufacturing lead Merck, as Head of Pharmaceutical Supplies and Development at Roche, and built and led the Drug Product Services Business Unit at Lonza.
Hanns-Christian launched ten23 health in 2021 as a CDMO with a strong focus on patients, people and planet. In 2024, the company inaugurated a new sterile manufacturing facility in Visp, Switzerland, obtained B Corporation, MyGreenLab and certification and SBTi target validation, for its commitment to social and environmental sustainability, and signed new partnerships with SHL Medical, Ypsomed, and BD.
“How can we attract more talented scientists to the field? Become part of the educational system! Motivate young people (especially girls) for STEM! I enjoyed a ‘medicine making’ project with kids in school (making hand creams) and we routinely host kids events at our ten23 labs.”
